The Science of Better Recovery
Positive allosteric modulators enhance natural receptor response, offering relief without the risks of high-dose traditional therapies.
Precision Neural Relief
Research proves that selective modulation provides a safer alternative for chronic pain management. Now this class of medication will need critical review and will need to meet standards of efficacy as outlined by the FDA.
Why PAMs?
Leading the shift towards non-opioid solutions through innovative pharmaceutical research.
Safer Profile
PAMs reduce side effects by modulating existing signals rather than overwhelming receptors.
Precision
Our staff work tirelessly to ensure that the drugs that they recommend to the FDA are safe and target relevant receptors only.
We prioritize patient long-term health by developing non-addictive, high-efficacy alternatives.
Future-Led
Contribute to our Mission
Aethel is developing precision neuromodulators for pain, beginning with mu-opioid receptor positive allosteric modulators designed to preserve analgesia while reducing the liabilities of conventional opioids. In parallel, Aethel is evaluating subtype-selective GABA_A modulation as an opioid-sparing and central-amplification strategy, guided by a platform framework that prioritizes selective signaling, partial efficacy, abuse-liability gating, and translational PK/PD.
